Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates
- 1 January 2003
- journal article
- Published by Springer Science and Business Media LLC in Journal of Neuro-Oncology
- Vol. 61 (3), 203-207
- https://doi.org/10.1023/a:1022592913323
Abstract
Temozolomide is a prodrug that undergoes spontaneous chemical degradation at physiologic pH to form the highly reactive alkylating agent, methyl-triazenyl imidazole carboxamide (MTIC). In clinical...Keywords
This publication has 13 references indexed in Scilit:
- Temozolomide and treatment of malignant glioma.2000
- Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First RelapseJournal of Clinical Oncology, 1999
- Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid MalignanciesJournal of Clinical Oncology, 1999
- Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer.1997
- Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cellsBritish Journal of Cancer, 1993
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- A RHESUS-MONKEY MODEL FOR CONTINUOUS INFUSION OF DRUGS INTO CEREBROSPINAL-FLUID1990
- ANTITUMOR IMIDAZOTETRAZINES .13. ANTITUMOR-ACTIVITY AND PHARMACOKINETICS IN MICE OF 8-CARBAMOYL-3-METHYL-IMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE (CCRG 81045-M-AND-B-39831), A NOVEL DRUG WITH POTENTIAL AS AN ALTERNATIVE TO DACARBAZINE1987
- DNA CROSS-LINKING AND CYTO-TOXICITY IN NORMAL AND TRANSFORMED HUMAN-CELLS TREATED INVITRO WITH 8-CARBAMOYL-3-(2-CHLOROETHYL)IMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE1984
- Mlab — A mathematical modeling toolComputer Programs in Biomedicine, 1979